Treatment of chronic migraine headache with onabotulinumtoxinA

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic migraine headache remains an exceedingly difficult entity to manage. Treatment of chronic migraine headache with onabotulinumtoxinA has recently been shown to be effective in reducing the severity and frequency of chronic migraine headache, in the PREEMPT trials, a landmark achievement. However, the studies use a primarily fixed dose and site approach to treatment, allowing some individualized injections. However, the authors do not address the issue of myofascial trigger points as potential triggers of migraine that could be inactivated using onabotulinumtoxinA, despite several studies that support the role of myofascial trigger points in initiating some migraine headaches.

Original languageEnglish (US)
Pages (from-to)336-338
Number of pages3
JournalCurrent pain and headache reports
Volume15
Issue number5
DOIs
StatePublished - Oct 2011

Keywords

  • Botulinum toxin A
  • Injection
  • MTrP
  • Migraine
  • Migraine trigger
  • Myofascial trigger points
  • Onabotulinumtoxin
  • Onabotulinumtoxina
  • PREEMPT 1
  • PREEMPT 2
  • PREEMPT trials
  • Referred pain
  • Trigger points

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Treatment of chronic migraine headache with onabotulinumtoxinA'. Together they form a unique fingerprint.

Cite this